Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study

Journal of Thrombosis and Haemostasis : JTH
Antonio P Arenas de LarrivaAaron R Folsom

Abstract

Essentials Ceruloplasmin (CP) is an acute-phase reactant and a potential biomarker of atherothrombotic risk. We assessed associations between CP and venous thromboembolism (VTE) risk in 9933 individuals. Higher circulating CP but not CP-related genes were associated with greater incident VTE rates. Circulating CP could be considered a non-causal biomarker of VTE risk in the community. SUMMARY: Background Ceruloplasmin (CP) is an acute-phase reactant and a potential biomarker of atherothrombotic risk. We assessed the associations between CP, CP-associated genetic variants and incident venous thomboembolism (VTE) in the Atherosclerosis Risk in Communities study. Methods and results In an observational study, 9933 men and women aged 53-75 years without prevalent VTE were included in 1996-1998 and followed through 2011. Circulating CP was measured in stored blood samples obtained in 1996-1998. Polymorphisms rs11708215 and rs13072552, which have been previously associated with CP concentrations, were measured in 8439 participants. VTEs were identified from hospital discharge codes and validated by physician review of medical records and imaging reports. Over a mean of 10.5 years of follow-up, 376 cases of VTE were identified. The as...Continue Reading

References

Apr 3, 1997·The New England Journal of Medicine·P M RidkerC H Hennekens
Oct 26, 2005·Journal of Thrombosis and Haemostasis : JTH·I Conde, J A López
Feb 26, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Thomas W WakefieldPeter K Henke
Oct 1, 2008·Journal of Internal Medicine·J P CasasM B Pepys
Mar 31, 2009·The New England Journal of Medicine·Robert J GlynnPaul M Ridker
Oct 7, 2009·Thrombosis and Haemostasis·Aaron R FolsomMary Cushman
Nov 28, 2009·Journal of the American College of Cardiology·Peter LibbyUNKNOWN Leducq Transatlantic Network on Atherothrombosis
Feb 27, 2010·European Heart Journal·Peter Libby, Filippo Crea
Apr 2, 2010·American Journal of Preventive Medicine·Michele G BeckmanThomas L Ortel
Apr 2, 2010·American Journal of Preventive Medicine·Gary E RaskobRichard H White
May 15, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Jeppe ZachoBørge G Nordestgaard
Jul 14, 2010·Journal of the American College of Cardiology·Samuel Z Goldhaber
Apr 13, 2012·Lancet·Samuel Z Goldhaber, Henri Bounameaux
Aug 17, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Peter Libby
Jul 19, 2013·Circulation. Heart Failure·Razvan T DaduChristie M Ballantyne
Nov 6, 2013·Journal of Internal Medicine·J Y Jeremy, N Shukla
Dec 7, 2013·Journal of Thrombosis and Thrombolysis·Signy V SveinsdottirGunnar Engström
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·John A HeitRichard H White

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.